Patents by Inventor Glenn C. Andrews

Glenn C. Andrews has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 4476312
    Abstract: Processes for preparing isometrically pure 3-methylthiophene-2-carboxaldehyde, an intermediate for synthesis of anthelmintic agents, by reaction of mercaptoacetaldehyde or the dimer, or a polymer thereof, or a dialkylacetal thereof in the presence of a base with (1) methyl vinyl ketone or an alpha- or beta- oxidized derivative of methyl vinyl ketone to form a 3-oxobutylmercaptoacetaldehyde or dialkyl acetal thereof, or an alpha- or beta-substituted derivative thereof which is then converted to 3-methylthiophene-2-carboxaldehyde via appropriate steps including, if necessary, treatment with acid, followed, if necessary, by enamine catalyzed cyclization and, in the case of using methyl vinyl ketone as reactant, a dehydrogenation step; or (2) 3-butyn-2-one to produce a mixture of isomeric 3-oxobut-1-enylmercaptoacetaldehyde or dialkyl acetals thereof which is cyclized to 3-methylthiophene-2-carboxaldehyde.
    Type: Grant
    Filed: February 17, 1984
    Date of Patent: October 9, 1984
    Assignee: Pfizer Inc.
    Inventor: Glenn C. Andrews
  • Patent number: 4471139
    Abstract: Processes for preparing isomerically pure 3-methylthiophene-2-carboxaldehyde, an intermediate for synthesis of anthelmintic agents, by reaction of mercaptoacetaldehyde or the dimer, or a polymer thereof, or a dialkylacetal thereof in the presence of a base with (1) methyl vinyl ketone or an alpha- or beta-oxidized derivative of methyl vinyl ketone to form a 3-oxobutylmercaptoacetaldehyde or dialkyl acetal thereof, or an alpha- or beta-substituted derivative thereof which is then converted to 3-methylthiophene-2-carboxaldehyde via appropriate steps including, if necessary, treatment with acid, followed, if necessary, by enamine catalyzed cyclization and, in the case of using methyl vinyl ketone as reactant, a dehydrogenation step; or (2) 3-butyn-2-one to produce a mixture of isomeric 3-oxobut-1-enylmercaptoacetaldehyde or dialkyl acetals thereof which is cyclized to 3-methylthiophene-2-carboxaldehyde.
    Type: Grant
    Filed: May 24, 1982
    Date of Patent: September 11, 1984
    Assignee: Pfizer Inc.
    Inventor: Glenn C. Andrews
  • Patent number: 4368330
    Abstract: 5,6-Anhydro-L-ascorbic acid, 5,6-anhydro-D-erythorbic acid and salts thereof are disclosed. Such compounds are useful intermediates in the preparation of 6-deoxy-6-substituted-L-ascorbic acid and 6-deoxy-6-substituted-D-erythorbic acid, which are useful as antioxidants. Novel 6-deoxy-6-substituted-L-ascorbic and -D-erythorbic acid derivatives are also disclosed.
    Type: Grant
    Filed: April 30, 1981
    Date of Patent: January 11, 1983
    Assignee: Pfizer Inc.
    Inventor: Glenn C. Andrews
  • Patent number: 4342695
    Abstract: 5-Keto-L-ascorbic acid-5,5-dimethyl ketal, alkali metal and alkaline earth metal salts thereof; process for the preparation thereof; its use as an antioxidant and intermediate for production of 5-keto-L-ascorbic acid and L-ascorbic acid. 5-keto-L-ascorbic acid and its 5,5-dimethyl ketal exhibit antiscorbutic activity.
    Type: Grant
    Filed: February 9, 1981
    Date of Patent: August 3, 1982
    Assignee: Pfizer Inc.
    Inventor: Glenn C. Andrews
  • Patent number: 4337350
    Abstract: The novel stereoselective and regioselective alkali metal borohydride reduction of 2,5-diketogluconic acid, alkyl esters or salts thereof to form 2-ketogulonic acid together with lesser amounts of 2-ketogluconic acid is disclosed. The 2-ketogulonic acid is readily converted to ascorbic acid.
    Type: Grant
    Filed: April 25, 1980
    Date of Patent: June 29, 1982
    Assignee: Pfizer Inc.
    Inventor: Glenn C. Andrews
  • Patent number: 4322557
    Abstract: 1-Aryloxy-2-(S)-hydroxy-3-(triarylphosphonio)-propane salts and alkali metal ylids thereof are novel intermediates useful in the direct synthesis of 15-(R)-hydroxy-16-aryloxy-prostaglandins.
    Type: Grant
    Filed: February 17, 1981
    Date of Patent: March 30, 1982
    Assignee: Pfizer Inc.
    Inventor: Glenn C. Andrews
  • Patent number: 4276219
    Abstract: 5-Keto-L-ascorbic acid-5,5-dimethyl ketal, alkali metal and alkaline earth metal salts thereof; process for the preparation thereof; its use as an antioxidant and intermediate for production of 5-keto-L-ascorbic acid and L-ascorbic acid. 5-Keto-L-ascorbic acid and its 5,5-dimethyl ketal exhibit antiscorbutic activity.
    Type: Grant
    Filed: July 20, 1979
    Date of Patent: June 30, 1981
    Assignee: Pfizer Inc.
    Inventor: Glenn C. Andrews
  • Patent number: 4230880
    Abstract: The novel stereoselective and regioselective alkali metal borohydride reduction of 2,5-diketogluconic acid, alkyl esters or salts thereof to form 2-ketogluconic acid together with lesser amounts of 2-ketogluconic acid is disclosed. The 2-ketogluconic acid is readily converted to ascorbic acid.
    Type: Grant
    Filed: February 16, 1979
    Date of Patent: October 28, 1980
    Assignee: Pfizer Inc.
    Inventor: Glenn C. Andrews
  • Patent number: 4212988
    Abstract: 2,5-Diketogluconic acid, alkyl esters or salts thereof, are reduced by an amine-borane to 2-ketogulonic acid, an intermediate for the preparation of ascorbic acid.
    Type: Grant
    Filed: March 26, 1979
    Date of Patent: July 15, 1980
    Assignee: Pfizer Inc.
    Inventor: Glenn C. Andrews
  • Patent number: 4159990
    Abstract: The novel stereoselective and regioselective alkali metal borohydride reduction of 2,5-diketogluconic acid, alkyl esters or salts thereof to form 2-ketogulonic acid together with lesser amounts of 2-ketogluconic acid is disclosed. The 2-ketogulonic acid is readily converted to ascorbic acid.
    Type: Grant
    Filed: October 20, 1977
    Date of Patent: July 3, 1979
    Assignee: Pfizer Inc.
    Inventor: Glenn C. Andrews